New p32/gC1qR Ligands for Targeted Tumor Drug Delivery

0301 basic medicine Aminopyridines Bioengineering Antineoplastic Agents Breast Neoplasms Ligands high-throughput screening Peptides, Cyclic Cell Line Mitochondrial Proteins Medicinal and Biomolecular Chemistry Mice 03 medical and health sciences Drug Delivery Systems Cell Line, Tumor Medicinal and biomolecular chemistry Nanotechnology cancer Animals Humans Cancer Cyclic Tumor Organic Chemistry Ethylenediamines 3. Good health 5.1 Pharmaceuticals Biochemistry and cell biology Chemical Sciences drug delivery peptides Nanoparticles nanoparticles Female Biochemistry and Cell Biology Development of treatments and therapeutic interventions Peptides Carrier Proteins Biotechnology
DOI: 10.1002/cbic.201500564 Publication Date: 2016-02-20T16:08:38Z
ABSTRACT
AbstractCell surface p32, the target of LyP‐1 homing peptide, is upregulated in tumors and atherosclerotic plaques and has been widely used as a receptor for systemic delivery of payloads. Here, we identified an improved LyP‐1‐mimicking peptide (TT1, CKRGARSTC). We used this peptide in a fluorescence polarization‐based high‐throughput screening of a 50 000‐compound chemical library and identified a panel of compounds that bind p32 with low micromolar affinity. Among the hits identified in the screen, two compounds were shown to specifically bind to p32 in multiple assays. One of these compounds was chosen for an in vivo study. Nanoparticles surface‐functionalized with this compound specifically adhered to surfaces coated with recombinant p32 and, when injected intravenously, homed to p32‐expressing breast tumors in mice. This compound provides a lead for the development of p32‐targeted affinity ligands that circumvent some of the limitations of peptide‐based probes in guided drug delivery.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (33)
CITATIONS (79)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....